Lakewood-Amedex Q2 FY26 net loss widens to $3.77 million; R&D expense more than doubled to $503,020
LABT•Financing and market listing update
Series C Convertible Preferred Stock private placement raised about $6.8 million net; common stock began trading on the Nasdaq Capital Market on April 23.
Quarterly loss widens as expenses increase
Lakewood-Amedex posted a net loss of $3.77 million for the quarter ended June 30, 2026, widening from the prior-year period.
Operating loss widened to $3.79 million as total operating expenses climbed to $3.79 million.
R&D spending rises on Nu-3 Phase 2a planning
Research and development spending more than doubled to $503,020, driven by higher manufacturing, regulatory and clinical planning for Nu-3 Phase 2a.
General and administrative costs jumped to $3.29 million, mainly due to $2.4 million in noncash professional services tied to stock issuance.
